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Abstract
Fire and Mello initiated the current explosion of interest in RNA interference (RNAi) biology with their seminal work in 
Caenorhabditis elegans. These observations were closely followed by the demonstration of RNAi in Drosophila 
melanogaster. However, the full potential of these new discoveries only became clear when Tuschl and colleagues 
showed that 21-22 bp RNA duplexes with 3" overhangs, termed small interfering (si)RNAs, could reliably execute RNAi 
in a range of mammalian cells. Soon afterwards, it became clear that many different human cell types had endogenous 
machinery, the RNA-induced silencing complex (RISC), which could be harnessed to silence any gene in the genome. 
Beyond the availability of a novel way to dissect biology, an important target validation tool was now available. More 
importantly, two key properties of the RNAi pathway - sequence-mediated specificity and potency - suggested that 
RNAi might be the most important pharmacological advance since the advent of protein therapeutics. The 
implications were profound. One could now envisage selecting disease-associated targets at will and expect to 
suppress proteins that had remained intractable to inhibition by conventional methods, such as small molecules. This 
review attempts to summarize the current understanding on siRNA lead discovery, the delivery of RNAi therapeutics, 
typical in vivo pharmacological profiles, preclinical safety evaluation and an overview of the 14 programs that have 
already entered clinical practice.
Introduction
Since the original reports of RNA interference (RNAi) in
cells from a range of species [1-3], there has been increas-
ing interest in harnessing this endogenous mechanism,
which enables degradation of a specific mRNA, as a novel
pharmacological approach to human disease. Indeed,
from a drug discovery perspective, small interfering
(si)RNAs have some distinct advantages over conven-
tional drug therapies such as small molecules or antibod-
ies (Table 1). However several major obstacles have had
to be overcome before the entry of RNAi therapeutics to
clinical trials. These include steps required for lead selec-
tion, the use of chemical modifications to confer appro-
priate biopharmaceutic properties, the design of
formulations that enable delivery to a target tissue, and
screening of these products for safety, including assess-
ments for potential off-target effects. These aspects are
addressed below and followed by a critical analysis of the
14 programs that have entered clinical development in
the past decade. This review does not cover the related
and rapidly expanding field of RNA therapeutics, which
addresses microRNAs (miRNAs) rather than messenger
mRNAs, as targets.
Lead discovery algorithms
We and others have developed high-throughput algo-
rithms to support screening and selection of a lead
siRNA. De Fougerolles et al. [4] reviewed the various
steps involved, which include a bioinformatic screen to
identify duplexes 19-23 bp in length with minimal off-tar-
get complementarity, small-scale synthesis of a panel of
siRNAs, in vitro assays for potency and nonspecific cyto-
toxicity, and assessment of in vivo pharmacology. Embed-
ded in this primary screen are subscreens for stability in a
biological matrix (for example, serum, cerebrospinal or
bronchoalveolar lavage fluid) relevant to the target tissue,
and additional screens for specificity (addressed below).
The ubiquitous nature of RNases requires that in most
cases, a lead siRNA needs to be stabilized. Increased sta-
bility can be achieved by chemically modifying the pri-
mary sequence. To date, the modifications used have
been phosphodiester to phosphorothioate modifications
on the backbone and 2"-O-methyl or other 2" substitu-
tions on the ribose moieties [5]. This strategy has been
influenced by the antisense oligonucleotide (ASO) field,
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in which both modifications have been used extensively
and which provides an accompanying body of safety data
in preclinical species and in humans. Many additional
modifications have been explored both for siRNAs and
ASOs [5], including locked nucleic acids, in which the 4"
carbon on the sugars is tethered to the 2" substituent,
although fewer molecules of this type have to date
reached clinical trials. For any given sequence, the num-
ber and position of the chemical modifications necessary
is variable and requires an empiric approach. Given that
chemical modifications, especially to the antisense or
'guide' strand of the duplex, can influence potency, each
round of modifications also requires a secondary screen
to determine maintenance of activity. However, at the end
of this type of screening process, lead siRNAs with IC50
values in the low single-digit picomolar to femtomolar
range can often be identified (Figure 1). The combination
of attractive mechanism of action, efficiency of siRNA
lead discovery and relative ease of siRNA manufacture
explain why both biotechnology and pharmaceutical
companies have shown great enthusiasm for RNAi thera-
peutics [6].
Delivering RNAi therapeutics
The ~14 kDa mass and polyanionic charge of a typical 21
bp siRNA duplex ensure that achieving good tissue bio-
availability is often a greater challenge than lead selection.
Despite this, both local and systemic delivery to various
t i s s u e  a n d  c e l l u l a r  c o m p a r t m e n t s  h a v e  b e e n  d e m o n -
strated preclinically [4,7,8]. For local delivery, administra-
tion of unmodified siRNA in simple formulations such as
saline has resulted in target mRNA knockdown in a wide
variety of tissues, including the respiratory and urogenital
epithelia, central nervous system and the eye. Most of the
local delivery studies have been in mice, and involve sub-
stantial doses, presumably associated with high local con-
centrations that drive cellular uptake. Although the exact
mechanism of uptake in most of these cases remains
unknown, some notable effects have been observed,
including decreasing respiratory syncitial virus (RSV) or
parainfluenza virus (PIV) infection in respiratory epithe-
lium [9,10], herpes simplex virus-2 infection in the vagi-
nal epithelium [11], 2',3'-cyclic nucleotide 3'-
phosphodiesterase expression in oligodendrocytes [12],
huntingtin expression in neurons [13], and vascular
endothelial growth factor (VEGF)-A [14] and VEGF
receptor (VEGFR)I [15] expression in ocular tissues.
Systemic delivery of RNAi therapeutics offers both the
greatest opportunities and challenges. An unmodified
saline-formulated siRNA injected intravenously is subject
to simultaneous RNase-mediated degradation and rapid
renal excretion. Hence, any attempts at systemic delivery
must involve mechanisms for increasing the circulation
half-life (t1/2) of the siRNA, its distribution to an appro-
priate tissue compartment and then its uptake, followed
by intracytoplasmic release and activity. In this regard,
the greatest success to date has been achieved with
respect to hepatic delivery, with three distinct
approaches, each involving a conjugated or formulated
siRNA, warranting review.
Soutschek et al. [16] were the first to report a delivery
strategy with significant translational potential. In a
mouse system, they demonstrated that cholesterol conju-
gation to the sense or 'passenger' strand of an ApoB-spe-
cific siRNA administered intravenously resulted in a
significant reduction in clearance and an associated 16-
fold increase in t1/2, relative to the unconjugated control
(Figure 2). Subsequent work elucidated that the change in
pharmacokinetic (PK) characteristics was secondary to
loading of the conjugated siRNA into circulating lipopro-
Table 1: A comparison of various drug discovery attributes of siRNAs and small molecules
siRNA Small molecule
Specificity High, sequence driven Low-medium, conformation driven
Potency Typically pM Variable
Number of accessible targets >>1000 500 to 1,000
Number of potential leads and backups >>10 to 100, depending on length of target <2 to 3
Speed to lead molecule 4 to 8 weeks 2 to 4 years
Species crossreactivity High Low
Manufacturing Common, rapid, scalable methods Variable, can be complexVaishnaw et al. Silence 2010, 1:14
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tein particles via the appended cholesterol moiety [17].
This also facilitated receptor-mediated uptake of the
siRNA into hepatocytes, and resulted in ~60% knock-
down of ApoB mRNA in the mouse liver [16]. Notably,
intravenous administration of cholesterol-conjugated
siRNAs targeting ApoB also resulted in efficient knock-
d o w n  o f  A p o B  m R N A  i n  t h e  j e j u n u m .  M o r e  r e c e n t l y ,
conjugation-based approaches with other ligands have
been used, such as prostate-specific membrane antigen
aptamer-siRNA conjugates to deliver drug to tumor cells
in vivo [18].
Two groups have reported liposomal nanoparticle
(LNP)-mediated delivery of siRNA to the liver, demon-
strating knockdown in the mouse [19] and the non-
human primate [20]. In both studies, the LNP formula-
tion, also known as a 'stable nucleic acid lipid particle'
(SNALP), was composed of several non-covalently asso-
ciated components (an ionizable lipid, polyethylene gly-
col (PEG)-lipid for prolonging t1/2, cholesterol, and a
neutral lipid) which self-assembled and encapsulated the
siRNA. Morrissey et al. [19] were able to show that rela-
tive to unencapsulated siRNA, LNPs that encapsulated a
variety of anti-hepatitis B virus (HBV) siRNAs showed
reduced plasma clearance and efficient hepatic uptake
with dose-dependent, potent (>1 log10) and durable
knockdown of circulating HBV DNA levels in a mouse
model of infection. Zimmermann et al. [20] also demon-
strated hepatic uptake of LNPs with specific knockdown
of ApoB in the non-human primate. The pharmacody-
namic (PD) profile in this study was notable not only for
the extent of hepatic ApoB mRNA knockdown (>80%),
but also for its translation to systemic lowering of low-
density lipoprotein cholesterol (LDLc) (by 82%) which
persisted for several weeks after a single dose. The latter
observation was particularly interesting because the drug
was undetectable in the liver of animals beyond 48 hrs,
suggesting an apparent PK-PD hysteresis. Recent work
with more sensitive quantitative PCR assays has clarified
that in fact the drug is present (and presumably stabilized
in RISC) a t all time points when PD is observed aft er
LNP-mediated siRNA delivery [21] (Alnylam Pharmaceu-
ticals Inc., unpublished observations, Renta Hutabarat).
Figure 1 Small interfering (si)RNA Lead selection. A large panel of siRNAs identified by a bioinformatic screen were synthesized and tested in vitro 
for activity against the transthyretin transcript as measured by quantitative PCR. The upper part of the panel shows the entire panel tested in parallel 
at a given nanomolar siRNA concentration, and data are shown in rank order of potency, with each vertical line representing an individual siRNA. The 
bottom panel illustrates in vitro dose response curves for a potent versus a less potent molecule.
Dose response of best candidates
IC50=7.0 pM
...versus a less efficient one
IC50=1.25 nM
0
20
40
60
80
100
120
140
160
1x10
-5 0.001 0.1 10
0.25
0.35
0.45
0.55
0.65
0.75
1x10
-5 0.001 0.1 10
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1
1.1
Singe dose screen of siRNAs
%
 
T
T
R
 
m
R
N
A
 
r
e
m
a
i
n
i
n
g
F
r
a
c
t
i
o
n
 
T
T
R
 
m
R
N
A
 
r
e
m
a
i
n
i
n
g
F
r
a
c
t
i
o
n
 
T
T
R
 
m
R
N
A
 
r
e
m
a
i
n
i
n
gVaishnaw et al. Silence 2010, 1:14
http://www.silencejournal.com/content/1/1/14
Page 4 of 13
The mechanism of ionizable LNP-mediated delivery has
been dissected, and in vivo it involves the opsonization of
the LNP by ApoE in the circulation, LDL receptor-medi-
ated uptake of the opsonized particles by hepatocytes,
and then endosomal release of siRNA into the cytoplasm
(Alnylam Pharmaceuticals Inc.) [22].
The third systemic delivery approach of note involves
multicomponent complexes. Rozema et al. [23] studied
particles composed of siRNA conjugated with a dynamic
polyconjugate and complexed with PEG to extend t1/2,
plus a liver targeting ligand, N-acetyl galactosamine
(NAG). This strategy was successfully used in rodents
and non-human primates to show potent and durable
hepatic ApoB knockdown with associated reduction in
circulating LDLc. Mechanistically, the role of NAG was
crucial, as its replacement with mannose abrogated
uptake by hepatocytes and instead directed delivery to
other hepatic cellular compartments such as Kupffer
cells. Bartlett et al. [24] used a similar multicomponent
concept but complexed a ribonucleotide reductase
(RRM2) siRNA to cationic cyclodextrin, along with PEG
and a targeting ligand, transferrin. In this system, the
transferrin allowed delivery to extrahepatic sites, and tar-
get mRNA knockdown was achieved in a subcutaneous
tumor xenograft.
Of the three hepatic delivery concepts above, the LNP-
mediated approach has received the most attention.
Recently, optimization of LNP structure and function has
resulted in potent in vivo knockdown at doses as low as
0.01 mg/kg [25] (whereas in local delivery (see above)
doses are typically >1 mg/kg). LNP-mediated delivery of
RNAi therapeutics has now been applied to several differ-
ent target mRNAs other than ApoB and has been
described in five species including the mouse, rat, ham-
ster, guinea pig and non-human primate [20,25-28]
(Alnylam Pharmaceuticals Inc., unpublished observa-
tions). In terms of pharmacology, the LNP experiments
have fully validated the drug-like behavior of siRNAs. For
all the LNP studies cited, there is a consistency of obser-
vations with respect to PD onset, which generally occurs
within 24 hrs with peak effects at 48-72 hrs; duration,
which lasts several weeks depending on the potency (and
perhaps stability) of the siRNA concerned; strict dose
dependency; and return of PD to baseline. Akinc et al.
[27] also elegantly showed reproducibility of effects with
multiple treatment cycles by giving a LNP-formulated
Factor VII siRNA once monthly. Many studies have also
confirmed the RNAi mechanism of action in vivo by
demonstrating (via 5" rapid amplification of cDNA ends
assay) the anticipated cleavage site in the target mRNA
and the lack of effect by identical LNP-mediated delivery
of an irrelevant siRNA [20,26-28]. Overall, the potency,
predictable and reproducible pharmacology across differ-
ent targets and species (as anticipated for an endogenous
mechanism), the selectivity and the clear mechanism of
action suggest a robust translational potential for LNP-
based hepatic delivery of RNAi therapeutics.
To fully exploit the therapeutic potential of RNAi, sys-
temic delivery beyond the liver will need to be accom-
plished, and indeed some creative approaches have been
reported. With optimization to further increase the cir-
culation t1/2 relative to LNPs delivering to the liver, LNP-
mediated extrahepatic delivery to subcutaneous tumors
in mice has been achieved [29]. Antibodies facilitating
siRNA delivery offer several advantages, including an
intrinsic targeting mechanism and good PK properties.
Antibody-protamine fusion proteins have been shown to
complex with siRNAs and reported to deliver specifically
to subcutaneous tissue [30] and to lung [31] tumors in
mice. By bringing together the advantages of LNPs and
antibodies, Peer et al. [32] devised sophisticated neutral
LNPs with a covalently attached antibody against β7 inte-
grin and carrying an anticyclin D1 siRNA complexed
with protamine. Using this approach, they were able to
show specific knockdown of cyclin D1 in gut mononu-
clear leucocytes with translation to therapeutic effects in
a mouse model of colitis. Oral delivery of RNAi therapeu-
tics would offer the greatest convenience if translatable
clinically. Recently, glucan-encapsulated siRNA particles
were reported to be efficient oral delivery vehicles to tar-
get gut macrophages [33]. Although the extrahepatic
delivery concepts above demonstrate progress, further
work is required to reproduce the observations and dem-
onstrate a clear RNAi-dependent mechanism of action,
much as described for extrahepatic delivery to subcuta-
neous tumors [29].
Figure 2 In vivo pharmacokinetic profile of a cholesterol-conju-
gated (squares) and unconjugated (circles) radio-labeled small 
interfering (si)RNA against ApoB in the mouse [16]. The half-life and 
clearance were calculated to be 95 minutes and 0.5 mL/minute and 6 
minutes and 17.6 mL/minute, for the conjugated and unconjugated 
molecules, respectively.
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Safety screening: in vitro
Several in vitro studies over the past decade have sug-
gested that RNAi therapeutics have the potential for off-
target effects [34]. These are potentially of three types:
sequence-dependent/RISC-mediated [35-37], sequence-
independent/RISC-mediated [38,39] and sequence-inde-
pendent/innate immune-mediated [40-42]. The first,
produced by binding of the sense or antisense strand to
bystander mRNA(s), might lead to an RNAi-mediated
off-target effect, or if hybridization occurs in the 3'
untranslated region (UTR) then potentially to miRNA-
like translational suppression. Bioinformatics, of course,
plays a crucial role in minimizing these potential liabili-
ties by deprioritizing sequences that have significant off-
target complementarity. Rarely, sequences of interest that
have high off-target potential cannot be avoided. In those
instances the relative on-target versus off-target half-
maximal inhibitory concentrations (IC50s) should be
determined in vitro (much as for small molecules). We
have found that this approach generally reveals that,
despite high degrees of off-target complementarity, in
vitro potency is clearly distinguishable with IC50s for on-
and off-target effects separated by several log orders (Fig-
ure 3).
Notwithstanding the utility of a robust bioinformatic
screening algorithm, multiple studies have detected wide-
spread transcript dysregulation [34]. Most of the studies
have relied on in vitro siRNA transfection followed by
transcriptome readouts. These types of datasets require
cautious interpretation for several reasons, including the
lack of clear cause and effect relationships (that is, how
much of the transcriptional dysregulation is secondary to
on-target versus off-target knockdown), the relatively
modest degree of transcript dysregulation described (typ-
ically an increase or decrease of ≤ two-fold) and the lack
of protein or functional readout. When protein correlates
have been examined, the siRNA-associated off-target
effects have resulted in either very subtle effects or in a
lack of quantitative relationship between change in
bystander mRNA and protein expression [43]. Finally,
studies examining off-target effects have used molecules
with suboptimal potency and specificity requiring
suprapharmacologic doses to achieve target knockdown.
For example, Bilanges and Stokoe [44] observed signifi-
cant off-target effects with ASO- and siRNA-based
approaches against a specific target, phosphoinositide-
dependent kinase (PDK)1; however, they used high,
potentially cytotoxic concentrations (>300 nM, in con-
trast to the pharmacologic (picomole to femtomole) lev-
els discussed above (Figure 1).
From a drug development viewpoint, it is widely
acknowledged that many molecules, including ASOs [45]
and small molecules, from acetaminophen [46] to kinase
inhibitors [47], all show diverse effects on transcriptional
profiling analyses. Nevertheless, preclinical transcrip-
tional profiling has not been routinely used in lead selec-
tion, as these effects have not been shown to have any in
vivo consequence in terms of safety or efficacy.
Sequence-independent off-target effects refer to either
saturation of the endogenous RISC machinery [38,39] or
to the immunostimulatory potential of siRNAs [48]. Sin-
gle-stranded and double-stranded RNAs, particularly
chemically unmodified sequences, can stimulate the
innate immune system via Toll-like receptor (TLR)-3
[14], TLR-7/8 [40-42] and non-TLR pathways, such as
retinoic acid inducible gene (RIG)-I [49] or PKR [50].
Cytokine induction can contribute to target suppression
via an RNAi-independent mechanism [14,51]. Eliminat-
ing this proinflammatory liability is therefore crucial
from both a safety and efficacy perspective. Tractable in
vitro [10,40] and in vivo [41,52] preclinical assays exist,
which can assess the proinflammatory potential of an
siRNA. Similar approaches were validated when proin-
flammatory DNA oligonucleotides acting as TLR-9 ago-
nists were studied preclinically and then in clinical
practice [53,54]. From a practical viewpoint, because
there is no a priori knowledge as to which pathway might
be engaged for any candidate siRNA, a wide range of
inflammatory markers should be evaluated during lead
selection, including type I and II interferons, and cytok-
ines and chemokines induced by TLR-3, TLR-7 and TLR-
8 agonists. The use of appropriate control siRNAs is cru-
cial in immunostimulatory screening assays, and a widely
used, chemically modified green fluorescent protein
(GFP) sequence has served as an important negative con-
trol for many groups [51]. In certain cases, a given
sequence with proinflammatory potential might be very
desirable for potency or other considerations. Fortu-
nately, both increased stability and reduced pro-inflam-
matory liabilities can be achieved simultaneously by
chemical modifications (Figure 4). Again, the process of
modification is empiric and requires subsequent confir-
mation that potency has been maintained. It is to be
hoped that greater knowledge of TLR recognition will
enhance bioinformatic exclusion of proinflammatory
sequences and guide chemical modification strategies to
specific motifs [40,41,55], increasing overall screening
efficiency and throughput.
Safety screening: in vivo
The entry of an RNAi therapeutic program into clinical
practice requires completion of good laboratory practice
(GLP)-compliant preclinical toxicological studies. Studies
in the rat and dog are used preclinically for the vast
majority of drugs destined for clinical practice. By con-
trast, ASO programs set a precedent by using mouse and
non-human primate [56]. It is our understanding that all
RNAi therapeutics currently in clinical trials used aVaishnaw et al. Silence 2010, 1:14
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rodent and non-human primate as preclinical toxicologi-
cal species. The reasons underlying this choice are the
same for ASO and RNAi programs, and include the avail-
ability of bioinformatic databases to enable design of a
single crossreactive siRNA for use in rodent, non-human
primates and humans; the ability to leverage prior animal
pharmacology work with the relevant siRNA; the avail-
ability of tools and assays such as immunological read-
outs and knockout mice; and finally the hope that the
non-human primate represents the closest physiology to
that of humans.
Some principles regarding the design of preclinical tox-
icology studies for RNAi programs are now discussed. In
both test species, low, medium and high exposures
s h o u l d  b e  a c h i e v e d  u s i n g  t h e  l o w  d o s e  a t  o r  n e a r  t h e
anticipated pharmacological dose and the highest dose to
represent a significant excess, allowing definition of a
maximum tolerated dose. Dosing schedule and timing of
terminal sacrifice should take into account the duration
of pharmacologic effect, given that single intravenous
doses can exert target mRNA knockdown for several
weeks, as discussed above. If the candidate siRNA is not
fully complementary to the target mRNA in both preclin-
ical species, then a sequence should be selected that is
crossreactive to at least one preclinical species, allowing
study of on-target toxicity secondary to target mRNA
knockdown. For systemic delivery programs, adequate
controls should be considered including, where appropri-
ate, comparison of formulated candidate siRNA, formu-
lated irrelevant siRNA and naked (unformulated) siRNA,
in order to dissect the relative contributions of siRNA
and formulation to the toxicological profile. Beyond the
safety endpoints that would be expected in a GLP toxico-
logical program, additional readouts of interest include
cytokines and chemokines, specifically those relating to
immunostimulation-related effects via TLR activation
(see above). Currently, it is not known which preclinical
species is most predictive of immunostimulation-medi-
ated effects but a combination of in vitro screening along
with in vivo readouts in two species before clinical trials
are held is an appropriately conservative approach.
Finally, suitable high-sensitivity bioanalytical assays need
to be incorporated to track the siRNA [57], formulation
components (if they contribute to the overall profile) and
associated metabolites.
Details of GLP toxicology programs are rarely pub-
lished, and few data are in the public domain. However,
no evidence to suggest toxicities similar to those seen
with first-generation ASO [56] has emerged. Accordingly,
there are no reports of siRNA-related complement acti-
vation, coagulation defects, immunostimulation and lym-
phoid hyperplasia or renal tubular changes. We and
Figure 3 Comparison of on- and off-target effects. A putative lead molecule was tested in vitro to evaluate potency against the intended target, 
transthyretin and four sequence-related off targets defined by the bioinformatic screen. The percentage reduction in transythyretin levels was mea-
sured by quantitative PCR.
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others have studied unformulated siRNAs at doses >100
mg/kg in the rodent and non-human primate and found
them to be well tolerated, although this is in all likelihood
secondary to the rapid renal elimination of naked (unfor-
mulated) siRNAs. For systemic delivery formulations
such as LNPs and multicomponent complexes with
approximate diameters of 50-110-15 nm, respectively,
particle size might be an important determinant of
biodistribution and therefore target organs for toxicity.
For these types of nanoparticles, vascular egress would be
expected predominantly in tissues with fenestrated (~100
nm apertures) microvasculature, such as liver, spleen and
bone marrow. Consistent with this and the substantial
blood flow through the liver, hepatic transaminase eleva-
tions were reported in association with LNPs [20] and
multicomponent complexes [24]. Abrams et al. [21] stud-
ied LNP201, a cationic LNP encapsulating an anti-SSB
siRNA. They demonstrated that LNP201 localized pre-
dominantly to liver and spleen, and with the use of appro-
priate controls found that the formulation (and not the
Figure 4 Profiling immunostimulatory small interfering (si)RNAs. (a) A panel of siRNAs including negative and positive controls were evaluated 
in an in vitro human peripheral blood mononuclear cell (PBMC) assay as described previously [10] with supernatants examined for tumor necrosis fac-
tor (TNF) (left panel) and interferon-α (right panel) levels. The right-hand side of each panel has a chemically unmodified siRNA, which is compared 
with the same sequence after incorporation of a combination of phosphorothioate and 2'-O-methyl chemical modifications. (b) The left-hand panels 
show a series of immunostimulatory (A-D) and non- immunostimulatory (X-Z) siRNAs evaluated in an in vitro PBMC assay. The right-hand panel shows 
plasma cytokine profiles in mice injected intravenously with the same siRNAs formulated in LNP01 [26]. Common immunostimulatory siRNAs are iden-
tified by the in vitro and in vivo assays.
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siRNA) had proinflammatory properties and at high
doses was associated with hepatotoxicity. The latter could
be abrogated by corticosteroid pretreatment. Thus, the
liver might come to be recognized as an important target
organ of toxicity as we learn more about systemic delivery
formulations.
Clinical RNAi pipeline
A total of 14 RNAi therapeutic programs have entered
clinical practice in the past decade (Table 2). Currently
few publications detailing these clinical experiences have
emerged, thus much of the information that follows has
had to be gleaned from corporate press releases or the US
National Institutes of Health hosted database of ongoing
and completed clinical trials http://www.clinicaltri-
als.gov. Of the 14 programs, seven involve local/topical
delivery to the eye (four), respiratory tract (two) and skin
(one). The remaining seven are systemic programs target-
ing liver (two), hepatic and extrahepatic cancer (three),
leukocytes (one) and kidney (one). All 14 programs are
being developed for indications with a high degree of
unmet medical need. A review of previous oligonucle-
otide programs reveals that the ASO field was hampered
until recently by a lack of clear proof of concept in
humans, largely because of two factors: poor target vali-
dation and lack of clear PD readouts in early clinical
development [58]. There is significant variability in the
degree of prior target validation across the global RNAi
pipeline. Six of the 14 programs (ALN-RSV, ALN-VSP,
ALN-TTR, TD101, bevasiranib, Bcr-abl) have clear target
validation, and the other eight programs address targets
of significant interest (for example, p53 for kidney injury
or RTP801 for age-related macular degeneration (AMD)),
but lack robust prior validation. Equally, only a few pro-
grams (ALN-TTR, ApoB-SNALP) offer the possibility of
early PD demonstration of target knockdown, whereas
the rest will require further development into phase II
before adequate proof of concept is achieved. ALN-RSV
has achieved initial proof of concept, and is discussed
separately below.
Table 2 shows how RNAi therapeutic programs demon-
s t r a t e  s o m e  o f  t h e  u n i q u e  a d v a n t a g e s  o f  t h e  p l a t f o r m .
Several have targets (RSV (N) nucleocapsid protein, p53,
TTR, ApoB, K6a) that would be 'undruggable' by small
molecules or protein moieties. The attempt to target Bcr-
abl and mutant K6a shows the potential for allele-specific
knockdown. Finally, ALN-VSP builds on data from ani-
mal models in which five transcripts were suppressed in
parallel [28] by simultaneously targeting two transcripts,
VEGF and kinesin spindle protein (KSP), a clear advan-
tage in complex indications such as cancer.
From an overall safety perspective, almost 1500
patients and healthy volunteers will soon have been
enrolled onto RNAi clinical programs. In total, 1065 have
already been studied across all phases of clinical develop-
ment, including 522 in the bevasiranib phase III studies.
These numbers are important because a unique siRNA-
related adverse event occurring at a high incidence (for
example >10%), would probably already have been identi-
fied. Equally, no data have emerged to suggest serious
adverse events linked to siRNA exposure, and none of the
programs have been placed on 'clinical hold' by regula-
tory agencies, a probable outcome if untoward safety
events were being uncovered. The largest fraction of the
safety experience (1284 subjects) relates to the three ocu-
lar programs (bevasiranib, PF-04523655 and
AGN211745) and to the respiratory program (ALN-
RSV), which suggests good local tolerability to RNAi
therapeutics.
ALN-RSV (Alnylam Pharmaceuticals Inc., Cambridge,
MA, USA) in phase 2b is currently the most advanced
program in the global RNAi pipeline. It uses an unmodi-
fied siRNA formulated in saline targeting the RSV N gene
transcript. Three phase I studies (two intranasal [59] and
one inhalational [60]) showed safety and tolerability at
doses up to 3 mg/kg. In 2008, this program reported the
first initial human proof of concept for an RNAi program.
In a double-blind, randomized, placebo-controlled study
(n  = 88) of safety and efficacy, prophylactic intranasal
treatment with ALN-RSV was shown to decrease the
incidence of experimental upper respiratory tract infec-
tion with RSV [60]. Since then, another double-blind,
randomized, placebo-controlled phase II study (n = 24)
has been completed with inhaled ALN-RSV in lung
transplant recipients naturally infected with RSV. The
findings demonstrated improved symptom scores and
lung function in favor of ALN-RSV, and the program will
shortly start a phase IIb study in the same indication [60].
The ALN-RSV program also illustrates the stability and
compatibility of RNAi therapeutics with devices, because
the inhalational delivery requires a nebulizer, and exten-
sive evaluation has demonstrated structural and func-
tional integrity of the drug before and after nebulization.
The drug PF-04523655 (Pfizer, NYC, NY, USA)is
administered via the intra-ocular route and targets
RTP801, a pro-angiogenic factor. It is currently in phase
II development for wet AMD [61] and diabetic macular
edema [62]; no further details are yet available. QPI-1002
(Quark Pharmaceuticals Inc., Fremont, CA, USA) is a
systemically administered siRNA targeting p53, which is
also in phase II development [63,64]. Two studies evaluat-
ing the safety of QPI-1002 in different patient populations
have been completed [65]. These include a phase I study
for the prevention of acute kidney injury in patients
undergoing major cardiovascular surgery, and the first
part of a phase I/II study in renal transplant recipients for
the prevention of delayed graft function. Both PF-
04523655 and QPI-1002 are thought to be in simple for-Vaishnaw et al. Silence 2010, 1:14
http://www.silencejournal.com/content/1/1/14
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Table 2: The global RNA interference pipeline*
Sponsor Program (clinical stage) Status Target Indication Number enrolled
Alnylam/Cubist/Kyowa 
Kirin
ALN-RSV (phase IIb) Ongoing RSV nucleocapsid Adult RSV infection 354
Pfizer/Quark PF-04523655 (phase II) Ongoing RTP801 (1)AMD, diabetic 
macular edema
244†
Quark QPI 1002 (phase II) Ongoing p53 (1)Acute kidney injury, 
delayed graft function
56†
Zabecor Excellair (phase II) Ongoing Syk kinase Asthma ?
Alnylam ALN-VSP (phase I) Ongoing VEGF, KSP Primary and 
secondary liver cancer
55†
Calando CALAA-01 (phase I) Ongoing RRM2 Cancer 36†
Silence Atu-027 (phase I) Ongoing PKN3 Cancer (GI, lung other) 33†
Sylentis SYL040012 (phase I) Ongoing β2 adrenergic 
receptor
Glaucoma ?
Alnylam ALN-TTR (phase I) Ongoing TTR TTR amyloidosis Enrollment begins 
H1, 2010
Opko Bevasiranib (phase III) Terminated VEGF-A AMD 522
Allergan/SIRNA AGN211745 (phase II) Terminated VEGFRI AMD 164
Tekmira ApoB SNALP (phase I) Completed ApoB Hypercholesterolemia 23
Transderm TD101 (phase I 
completed)
Completed Mutant K6a Pachyonychia 
congenita
1
Univ. Duisberg-Essen‡ Bcr-abl (phase I 
completed)
Unknown Bcr-abl oncogene CML 1
AMD = age-related macular degeneration; CML = chronic myeloid leukemia; GI = gastrointestinal; KSP = kinesin spindle protein; PKN = protein 
kinase N3; RRM2 = ribonucleotide reductase M2; RSV = respiratory syncytial virus; RTP = ; TTR = transthyretin; VEGF = vascular endothelial growth 
factor; VEGFRI = vascular endothelial growth factor receptor I.
*All data from corporate websites, press releases and http://www.clinicaltrials.gov
†Enrollment ongoing
‡From Koldehoff et al., 2007
mulations, but the exact details are not known. The three
cancer programs, ALN-VSP (Alnylam Pharmaceuticals
Inc.) [66], CALAA-01 (Calando Pharmaceuticals, Pasa-
dena, CA, USA) [67] and Atu-027 (Silence Therapeutics,
London, UK) [68] are all systemic delivery approaches
that are in phase I studies. ALN-VSP and Atu-027 rely on
LNP-mediated delivery [60,69] whereas CALAA-01
deploys a multicomponent complex delivery system [25].
All three programs are at early stages and no data have
yet been released, although preliminary ALN-VSP data
are expected by mid 2010. No data are available for the
ast hma pr ogram, Ex ce llair (tar geting syk kinase), ot her
than that in phase I, a total of 21 daily inhalational doses
were well tolerated [70].
Most recently, Tekmira Pharmaceuticals' (Burnaby, BC,
Canada) systemic delivery program Apo-B SNALP com-Vaishnaw et al. Silence 2010, 1:14
http://www.silencejournal.com/content/1/1/14
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pleted its phase I study, providing some of the earliest
systemic delivery results with an RNAi therapeutic. In
total, 23 adult volunteers with mild hypercholesterolemia
were enrolled, of whom 17 were exposed to Apo-B
SNALP (Apo-B siRNA in an LNP formulation), the rest
receiving placebo. Of three patients treated at the highest
dose, 0.6 mg/kg, one experienced flu-like symptoms
attributed to the siRNA; no other laboratory abnormali-
ties (including changes in liver function tests) or safety
events were reported. Interestingly, two of the patients on
this dose patients showed reductions in circulating LDLc
of 16.3% to 21.1% [71].
As would be expected, several RNAi therapeutic pro-
grams have been terminated. Bevasiranib (Opko Health
Inc., Miami, FL, USA) is delivered via the intravitreal
route and targets VEGF. In 2006, a randomized, double-
blind, phase II study comparing three doses was com-
pleted patients with in wet AMD (n  = 129) [72]. The
safety data were encouraging, but the absence of a pla-
cebo arm prevented interpretation of any efficacy signals.
Despite this limitation, and a report that its efficacy
might be mediated via TLR-3 activation [14], 330 patients
were enrolled in a phase III trial to study the safety and
efficacy of bevasiranib in wet AMD [73]. Unfortunately,
the study was terminated prematurely after the Indepen-
dent Data Monitoring Committee reported that although
safety was acceptable, the study was unlikely to reach its
primary endpoint, an improvement in visual acuity [74].
Similarly, the intravitreal program AGN211745 (Allergan
Inc., Irvine, CA, USA) which targets VEGFRI for wet
AMD, was also terminated in phase II [75] after initial
positive reports of efficacy from an earlier study [76].
AGN211745 too was shown to be possibly mediating its
effects in preclinical models of AMD via TLR-3 activation
[14].
From all the RNAi programs to date, only two, Bcr-abl
and TD101 (Transderm Inc., Santa Cruz, CA, USA), are
currently associated with completed safety and efficacy
s t u d i e s  t h a t  h a v e  b e e n  p u b l i s h e d .  H o w e v e r ,  b o t h  p r o -
grams enrolled only one patient each. Koldehoff et al. [77]
treated a single patient with recurrent CML by systemic
administration of a formulated siRNA against Bcr-abl;
however, the reported proof of concept with Bcr-abl
knockdown in circulating leukemic cells is difficult to
interpret because of the use of concomitant medications.
Leachman et al. [78] reported a phase 1b study in a single
patient with pachyonychia congenita, an autosomal dom-
inant condition with painful palmoplantar calluses sec-
ondary to a keratin K6a mutation. The safety and efficacy
of TD101 was tested in a 17-week, prospective, double-
blind, split-body, vehicle-controlled, dose-escalation trial
on a single patient. Randomly assigned solutions of
TD101 or vehicle control were injected into symmetric
plantar calluses on the opposite feet. No adverse events
occurred during the trial or in the 3-month washout
period. Subjective patient assessment and physician clini-
cal efficacy measures revealed regression of callus on the
siRNA-treated, but not on the vehicle-treated foot.
Conclusions
With barely a decade since its initial characterization, the
translation of RNAi biology toward RNAi therapeutics
has progressed at a rapid pace. Moreover, the following
years promise to be crucial for demonstration of the
safety and efficacy of this new method in controlled, ran-
domized studies. Certainly, much remains to be accom-
plished. In delivery research and preclinical studies,
further advancement of the field will require continued
progress in conjugation and formulation strategies. It
would be naive to believe that any one single technology
will provide all the solutions, so it is gratifying to see such
a broad-based effort across multiple delivery technolo-
gies under investigation in academia and industry. In
development efforts, many milestones remain to be
achieved, including the conduct of large phase III studies
and regulatory approvals. Of course, it is likely that there
will be product failures, which could be accounted for by
a number of factors including target selection, delivery
technologies, clinical trial design and even commercial
considerations. Nevertheless, the steadfast commitment
in the field is apparent in the advancement of this criti-
cally needed innovation to patients.
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